Full-Time

Patient Recruitment Associate I

Posted on 3/13/2025

Icon

Icon

10,001+ employees

Consulting and development services for pharmaceuticals

No salary listed

Entry, Junior

Company Does Not Provide H1B Sponsorship

Remote in USA + 1 more

More locations: Remote in Canada

100% Home-Based; candidates can be based in the United States, Canada, or Mexico.

Category
Human Resources
People & HR
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
Requirements
  • Bachelors degree, preferably in a healthcare/scientific field
  • An interest in clinical research
  • Basic understanding of medical terminology
  • Excellent communication and interpersonal skills
  • Comfortability fielding inbound and outbound phone calls
  • Ability to multitask
  • Organizational skills with attention to detail
  • Ability to work under pressure and with tight deadlines
  • Computer skills, specifically with Microsoft Office Suite (Excel, Word, Outlook)
Responsibilities
  • Screen potential study participants accordingly to protocol inclusion and exclusion criteria by asking study specific questions
  • Review, enter, and edit patient information into clinical trial management software
  • Book patients into site schedulers ensuring that entries are accurate and up to date
  • Read and understand the purpose and inclusion/exclusion criteria for each protocol
  • Respond to all leads within a 24-hour time period
  • Identify appropriate study opportunities for interested volunteers based on knowledge of clinical trials and neighboring locations
  • Problem solve and create contingency plans to optimize enrollment
  • Effectively communicate the importance of research participation to volunteers
  • Provide an exceptional patient experience by building positive rapport and consistent follow-up
  • Strive to meet personal and team targets
  • Work in strict confidentiality in all forms including electronically, written forms, and verbal
  • Remain accountable for delivering high quality, accurate work, ensuring all administration is filed accordingly
Desired Qualifications
  • Experience in customer service, marketing, or sales (preferred)

Icon provides consulting, development, and commercialization services to help clients in the pharmaceutical and medical device industries accelerate the creation of products that enhance health and well-being. Their services are designed to streamline the process of bringing drugs and devices to market by focusing on reducing time and costs while improving quality. With a presence in 53 countries, Icon leverages a global network of experts who have experience across various therapeutic areas. This extensive expertise allows them to tailor their solutions to meet the specific needs of their clients, setting them apart from competitors who may not offer the same level of specialized support. Icon's goal is to ensure that life-saving and life-improving products reach the market efficiently and effectively.

Company Size

10,001+

Company Stage

IPO

Headquarters

Ireland

Founded

1990

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with Mural Health enhances participant experience in clinical trials.
  • Increased use of AI optimizes trial methodologies and patient recruitment.
  • Recognition as a climate leader boosts ICON's appeal to socially conscious clients.

What critics are saying

  • Securities fraud lawsuit may impact investor confidence and financial stability.
  • Emerging CROs with advanced technologies pose competitive threats to ICON.
  • Challenges in optimizing biomarker technologies could hinder neurodegenerative research competitiveness.

What makes Icon unique

  • ICON leverages AI to accelerate biomarker detection in clinical trials.
  • The company focuses on patient-centric technologies like Mural Link for trial management.
  • ICON is recognized for its strong ESG practices, enhancing its industry reputation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Paid Vacation

401(k) Retirement Plan

Mental Health Support

Life Insurance

Flexible Work Hours

Company News

Rewbix
Mar 21st, 2025
Legal Turmoil for ICON Public Limited Company (ICLR): A Deep Dive into the Financial Impact of Securities Fraud Lawsuit

ICON Public Limited Company (ICLR), a leading healthcare and pharmaceutical services provider, has been hit by a securities fraud class-action lawsuit.

Rewbix
Mar 16th, 2025
Securities Fraud Class Action Lawsuit Filed Against ICON Public Limited Company (ICLR)

The law firm Kessler Topaz Meltzer & Check, LLP announced on March 16, 2025, that it has filed a securities fraud class action lawsuit against ICON Public Limited Company (ICLR).

PharmiWeb
Mar 4th, 2025
​​Mural Health And Icon Announce Partnership To Enhance Participant And Site Experience In Clinical Trials​

BERWYN, PENNSYLVANIA and DUBLIN, IRELAND, 4 March 2025 - Mural Health Technologies, Inc., a patient-first clinical trial technology company, and ICON plc (NASDAQ: ICLR), a global healthcare intelligence and clinical research organisation, today announce a partnership to utilise the participant management and payments platform, Mural Link. ICON will ​utilise​ Mural Link’s innovative functionality related to clinical trial participant payments, tax management, travel and concierge support, site-participant communication tools, and novel reporting and analytics capabilities. “From our very first conversations with ICON, we were highly impressed by their commitment to patient care and innovation,” said Sam Whitaker, CEO of Mural Health. “This partnership represents a shared vision of removing barriers to trial participation​ and advancing participation financial neutrality​, while eliminating the need for site staff to manage highly manual, error-prone, and time-consuming administrative activities.”

PharmiWeb
Jan 9th, 2025
Biomarker And Trial Optimisation Needed To Drive R&D Progress In Alzheimer’S And Related Disorders – Icon Survey

Dublin, Ireland – 8 January 2024 – ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of over 120 biotech and pharma professionals developing treatments for neurodegenerative disorders. The findings indicate that, despite recent successes in developing disease modifying treatments for Alzheimer's, persistent challenges that remain in neurodegenerative clinical trials can be mitigated by underutilised trial methodologies. ICON outlines how these innovations, including increased use of biomarkers and innovative trial designs, can be implemented in its new whitepaper: ‘Early, precise and efficient: The methods and technologies advancing Alzheimer’s and Parkinson’s RD’. Biomarkers are one of the most promising tools to identify potential clinical trial participants early in their disease progression. Encouragingly, nearly all respondents (97%) reported using biomarkers to identify patients and over half (59%) are leveraging AI tools to accelerate biomarker detection. Whilst this uptake is promising, biomarkers are not yet being optimised for full implementation

PharmiWeb
Dec 19th, 2024
Icon Announces Appointment Of Chief Operating Officer

Dublin, Ireland – 18 December 2024 –ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced the appointment of Barry Balfe as Chief Operating Officer (COO).Barry is a long-tenured ICON employee with over 20 years of service and brings extensive leadership experience and capability to the role of COO. He has held a number of leadership roles across both full service and functional solutions at ICON and has very successfully supported the growth of new and existing customer partnerships. His strong focus and track record on operational excellence, quality & delivery will enable the company to deliver greater value to our customers and further enhance our strategy to become the healthcare intelligence partner of choice in the industry.Barry will continue to report to ICON’s Chief Executive Officer, Steve Cutler.“Barry is a vastly experienced leader and has a very strong reputation across the industry” said Steve Cutler, ICON’s CEO “He has successfully led our largest division over the past number of years, creating and sustaining strategic partnerships with customers that have been key to our growth trajectory as a company. I look forward to working closely with Barry to drive further growth across the organisation, as we create value for our customers in delivering their clinical development programs more efficiently.”“It is a privilege to serve as ICON’s Chief Operating Officer,” said Barry Balfe. “I look forward to working with all of our dedicated colleagues around the world as we continue to drive superior innovation, execution and delivery for customers and for patients.”About ICON plcICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations

INACTIVE